Korean Govt’s Role To Boost Biopharma Should Sync With Maturity
Differentiated Strategy Required
A recent report suggests how the South Korean government’s role in boosting the biopharma industry should differ from other countries due to variations in the development stage and status of the components of the industry, requiring a more segmented and tailored approach as it strives for flagship status.
